Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 4/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.50 |
| ▸ | FAP | Q12884 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969587 | 0.85 | SMYD3 (0.61) | HDAC8POLBSMYD3OPRD1ROCK2 | |
| SCHEMBL6164884 | 0.83 | OPRD1 (0.60) | HDAC8POLBSMYD3OPRD1ROCK2 | |
| SCHEMBL6052747 | 0.83 | HDAC8 (0.59) | HDAC8POLBOPRD1DPP4DPP8 | |
| SCHEMBL4095232 | 0.83 | HDAC8 (0.59) | HDAC8POLBOPRD1DPP4DPP8 | |
| SCHEMBL4086820 | 0.83 | HDAC8 (0.59) | HDAC8POLBOPRD1DPP4DPP8 | |
| SCHEMBL6161830 | 0.80 | OPRD1 (0.65) | HDAC8POLBSMYD3OPRD1DPP4 | |
| SCHEMBL3133533 | 0.80 | OPRD1 (0.65) | HDAC8POLBSMYD3OPRD1DPP4 | |
| SCHEMBL15927802 | 0.80 | DPP4 (0.58) | HDAC8POLBOPRD1ROCK2CYP3A4 | |
| SCHEMBL7360693 | 0.79 | HPGD (0.66) | HDAC8POLBSMYD3OPRD1DPP4 | |
| Hydrochloric Acid SCHEMBL6163295 | 0.79 | HDAC8 (0.63) | HDAC8POLBSMYD3OPRD1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198693-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2004-10-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198693-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | HDAC8 1791/4885POLB 2299/4885SMYD3 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.